Announcements Trials
Browse Landscape

Phase

Phase 4 11Phase 2 8Phase 3 4Phase NA 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Neoplasms 1Keratosis, Actinic 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Diclofenac × Clear all
NCT01596647 2020-12-21

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

NCT01742663 2014-01-22

A Study Comparing Diclofenac Sodium Gel 3% to SolarazeĀ® Gel 3% in the Treatment of Actinic Keratosis

Sun Pharmaceutical Industries, Inc.

Phase 1 Completed
435 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon ⚔